Human kidney organoids model acute injury in the lab

At Monash University, researchers have grown microscopic, living human kidney organoids from stem cells and used them to model acute kidney injury (AKI), a sudden loss of kidney function. Led by Dr. Alexander Combes, the team’s work gives researchers a controlled way to watch kidney cells respond to injury.

AKI can occur during major surgery, transplantation or after exposure to some medicines, including chemotherapy. Professor John Kanellis, director of nephrology at Monash Health, said it affects up to 20% of hospital admissions. The injury may resolve, but it can also leave persistent damage that contributes to chronic kidney disease.

The organoids reproduce key features of human kidney injury. The published study, in Genome Medicine, examines injury-associated epithelial states and the interaction between macrophages and epithelial cells, helping the researchers investigate why some kidney cells recover while others do not.

Combes and his team are now working to screen potential therapies with the organoid platform. One target is drug repurposing: medicines already approved for other uses could, in principle, shorten the path to clinical use because established safety and clinical data are available. The source does not report a treatment ready for patients or results from a clinical trial.

So what changes in practice? For now, nothing at the bedside: the work remains a laboratory model. For kidney researchers, however, it creates a human system in which candidate treatments can be compared and the biology of recovery studied. The stated goal is to find therapies that protect the kidney or improve recovery after AKI, potentially reducing the damage that persists after the initial event.